Penicillamine

British Journal of Rheumatology

Volumn 36, Issue 1, 1997, Pages 104-109

  Munro, R ^a   Capell, H A ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; GOLD; HYDROXYCHLOROQUINE; IRON DERIVATIVE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

APLASTIC ANEMIA; BRONCHIOLITIS; CLINICAL TRIAL; DRUG MECHANISM; DYSGEUSIA; FETOTOXICITY; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LEUKOPENIA; LICHEN PLANUS; LIVER DYSFUNCTION; META ANALYSIS; MOUTH ULCER; MYASTHENIA GRAVIS; NAUSEA; ORAL DRUG ADMINISTRATION; PEMPHIGUS; POLYMYOSITIS; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; URTICARIA;

EID: 26844530621     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/36.1.104     Document Type: Review

References (54)

1. Jaffe IA. Comparison of the effect of plasmapheresis and penicillamine on the level of circulating rheumatoid factor. Ann Rheum Dis 1963;22:71-6.
2. Kukovetz WR, Beubler E, Kreuzig F, Moritz AJ, Nernberger G, Werner-Breitenecker L. Bioavailability and pharmokinetics of D-penicillamine. J Rheumatol 1983;10:90-4.
3. Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG. Reduction in oral penicillamine absorption by food, antacid and ferrous sulphate. Clin Pharmacol Ther 1983;33:465-70.
4. Schuna A, Osman MA, Patel RB, Welling PG, Sundstrom WR. Influences of food on the bioavailability of penicillamine. J Rheumatol 1983;10:95-7.
5. Perret D. The metabolism and pharmacology of D-penicillamine in man. J Rheumatol 1981;8(suppl. 7):41-50.
6. Muijser AO, van de Stadt RJ, Henrichs AM, Ament HJ, van der Korst JK. D-penicillamine in patients with rheumatoid arthritis. Serum levels, pharmokinetics aspects and correlation with clinical course and side-effects. Arthritis Rheum 1984;27:1362-9.
7. Jaffe IA. The effects of penicillamine on the laboratory parameters in rheumatoid arthritis. Arthritis Rheum 1965;8:1064-79.
8. Wernick R, Merryman P, Jaffe I, Ziff M. IgG and IgM rheumatoid factors in rheumatoid arthritis. Quantitative response to penicillamine therapy and relationship to disease activity. Arthritis Rheum 1983;26:593-8.
9. Lewins EG, Cripps AW, Clancy RL, Major GA. Penicillamine-induced immunosuppression: in vitro studies of inhibition of immunoglobulin synthesis. J Rheumatol 1982;9:677-84.
10. 4. J Clin Invest 1980;65:1069-76.
11. Matsubara T, Hirohata K. Suppression of human fibroblast proliferation by D-penicillamine and copper sulphate in vitro. Arthritis Rheum 1988;31:964-72.
12. 2 and HOCl. Ann Rheum Dis 1992;51:321-5.
13. Cuperus RA, Muijser AO, Wever R. Antiarthritic drugs containing thiol groups scavenge hypochlorite and inhibit its formation by myeloperoxidase from human leukocytes. Arthritis Rheum 1985;11:1228-33.
14. Multi-centre Trial Group. Controlled trial of D(-)penicillamine in severe rheumatoid arthritis. Lancet 1973;1:275-80.
15. Dixon A StJ, Davis J, Dormandy TL et al. Synthetic (D-)penicillamine in rheumatoid arthritis. Ann Rheum Dis 1975;34:416-21.
16. Shiokawa Y, Horiuchi Y, Honma M, Kageyama T, Okada T, Azuma T. Clinical evaluation of D-penicillamine by multicentric double-blind comparative study in chronic rheumatoid arthritis. Arthritis Rheum 1977;20:1464-72.
17. Williams HJ, Ward JR, Reading JC et al. Low-dose D-penicillamine therapy in rheumatoid arthritis. Arthritis Rheum 1983;26:581-92.
18. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line agents in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990;33:1449-61.
19. Capell HA, Marabani M, Madhok R, Torley H, Hunter JA. Degree and extent of response to sulphasalazine or penicillamine therapy for rheumatoid arthritis: results from a routine clinical environment over a two year period. Q J Med 1990;75:335-44.
20. Hochberg MC. Auranofin or D-penicillamine in the treatment of rheumatoid arthritis. Ann Intern Med 1986;105:528-35.
21. Bunch TW, O'Duffy JD, Tompkins RB, O'Fallon WM. Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis Rheum 1984;27:267-76.
22. Berry H, Liyange SP, Durance RA, Barnes CG, Berger LA, Evans S. Azathioprine and penicillamine in the treatment of rheumatoid arthritis: a controlled trial. Br Med J 1976;1:1052-4.
23. Paulus HE, Williams HJ, Ward JR et al. Azathioprine versus D-penicillamine in rheumatoid arthritis patients who have been treated unsuccessfully with gold. Arthritis Rheum 1984;27:721-7.
24. Huskinson EC, Gibson TJ, Balme HW et al. Trial comparing D-penicillamine and gold in rheumatoid arthritis. Ann Rheum Dis 1974;33:532-5.
25. Thomas MH, Rothermuch NO, Philps VK, Bergen W, Hendrick SW. Gold vs D-penicillamine double blind and followup. J Rheumatol 1984;11:764-7.
26. Scott DL, Greenwood A, Davies J, Maddison PJ, Maddison MC, Hall ND. Radiological progression in rheumatoid arthritis: do D-penicillamine and hydroxychloroquine have different effects? Br J Rheumatol 1990;29:126-7.
27. Gibson T, Huskisson EC, Wojtulewski JA et al. Evidence that D-penicillamine alters the course of rheumatoid arthritis. Rheumatol Rehabil 1976;15:211-5.
28. Porter DR, McInnes I, Hunter J, Capell HA. Outcome of second line therapy in rheumatoid arthritis. Ann Rheum Dis 1994;53:812-5.
29. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
30. Gibson T, Emery P, Armstrong RD, Crisp AJ, Panayi GS. Combined D-penicillamine and chloroquine in the treatment of rheumatoid arthritis - a comparative study. Br J Rheumatol 1987;26:279-284.
31. Taggart AJ, Hill J, Astbury C et al. Sulphasalazine alone or in combination with D-penicillamine in the treatment of rheumatoid arthritis. Br J Rheumatol 1987;26:32-6.
32. Dawes PT, Sheeran TP, Fowler PD, Shadforth MF. Improving the response to gold or D-penicillamine by addition of sulphasalazine. A pilot study in 25 patients with rheumatoid arthritis. Clin Exp Rheumatol 1987; 5:151-3.
33. McKenna F, Hopkins R, Hinchcliff KP, Bird HA, Wright V. Gold and penicillamine alone and in combination in active rheumatoid arthritis. ILAR 1985 XVIth International Congress of Rheumatology, p. 158 (abstracts).
34. Bitter T. Combined disease modifying chemotherapy for intractable rheumatoid arthritis. Clin Rheum Dis 1984;10:417-28.
35. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993;36:297-306.
36. Situnayake RD, Grindulis KA, McConkey B. Longterm treatment of rheumatoid arthritis with sulphasalazine, gold and penicillamine: a comparison using life table methods. Ann Rheum Dis 1987;46:177-83.
37. Howard-Lock HE, Lock CJ, Mewa A, Kean WF. D-penicillamine: chemistry and clinical use in rheumatoid disease. Semin Arthritis Rheum 1986;15:261-81.
38. Davison AM, Dat AT, Golding JR, Thomson D. Effects of penicillamine on the kidney. Proc R Soc Med 1977;70(suppl. 3):109-12.
39. Hall CJ, Jawad S, Harrison PR et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. Br Med J 1988;296:1083-6.
40. Thomas D, Gallus AA, Brooks PM et al. Thrombokinetics in patients with rheumatoid arthritis treated with penicillamine. Ann Rheum Dis 1984;43:402-6.
41. Andonopoulos AP, Terzis E, Tsibri E, Papasteriades CA, Papapetropoulos T. D-penicillamine induced myasthenia gravis in rheumatoid arthritis: an unpredictable common occurrence? Clin Rheumatol 1994;13:586-8.
42. Delamere JP, Jobson S, McIntosh LP et al. Penicillamine induced myasthenia in rheumatoid arthritis: its clinical and genetic features. Ann Rheum Dis 1983;42:500-4.
43. Carroll GJ, Will RK, Peter JB et al. Penicillamine induced polymyositis and dermatomyositis. J Rheumatol 1987;14:995-1001.
44. Gibson T, Burry HC, Ogg C. Goodpastures syndrome and penicillamine. Ann Intern Med 1976;84:100.
45. Chalmers A, Thompson D, Stein HE, Reid G, Patterson AC. Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis. Ann Intern Med 1982;97:659-63.
46. Levy RS, Fisher M, Alter JN. Penicillamine: review and cutaneous manifestations. J Am Acad Dermatol 1983;8:548-88.
47. Doyle DR, McCurley TL, Sergent JS. Fatal polymyositis in D-penicillamine treated rheumatoid arthritis. Ann Intern Med 1983;98:327-30.
48. Taylor PJ, Cumming DC, Corneblum B. Successful treatment of D-penicillamine induced breast gigantism with danazol. Br Med J 1981;282:362-3.
49. Rosa FW. Teratogen update: penicillamine. Teratology 1986;33:127-31.
50. Emery P, Panayi GS, Huston G et al. D-penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol 1984;11:626-32.
51. Bernelot Moens HJ, Ament HJ, Feltkamp TE, van der Korst JK. Longterm follow-up of treatment with D-penicillamine in rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens. J Rheumatol 1987;14:1115-9.
52. Madhok R, Zoma A, Torley HI et al. The relationship of sulphoxidation status to the efficacy and toxicity of penicillamine in the treatment of rheumatoid arthritis. Arthritis Rheum 1990;33:574-7.
53. Wolfe F, Schurle DR, Lin JJ et al. Upper and lower airways disease in penicillamine treated patients with rheumatoid arthritis. J Rheumatol 1983;10:406.
54. Seidman P, Lindstrom B. Pharmacokinetic interactions of penicillamine in rheumatoid arthritis. J Rheumatol 1989;16:473-4.